ES3050125T3 - Bromocriptine formulations - Google Patents

Bromocriptine formulations

Info

Publication number
ES3050125T3
ES3050125T3 ES23214280T ES23214280T ES3050125T3 ES 3050125 T3 ES3050125 T3 ES 3050125T3 ES 23214280 T ES23214280 T ES 23214280T ES 23214280 T ES23214280 T ES 23214280T ES 3050125 T3 ES3050125 T3 ES 3050125T3
Authority
ES
Spain
Prior art keywords
bromocriptine
approximately
bromocriptine mesylate
particle size
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES23214280T
Other languages
English (en)
Spanish (es)
Inventor
Anthony Cinotta
Craig Michael Bowe
Paul Clark Stearns
Laura Jean Weston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veroscience LLC
Original Assignee
Veroscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veroscience LLC filed Critical Veroscience LLC
Application granted granted Critical
Publication of ES3050125T3 publication Critical patent/ES3050125T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES23214280T 2012-04-30 2013-04-29 Bromocriptine formulations Active ES3050125T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/460,452 US8431155B1 (en) 2012-04-30 2012-04-30 Bromocriptine formulations

Publications (1)

Publication Number Publication Date
ES3050125T3 true ES3050125T3 (en) 2025-12-19

Family

ID=48146046

Family Applications (4)

Application Number Title Priority Date Filing Date
ES23214280T Active ES3050125T3 (en) 2012-04-30 2013-04-29 Bromocriptine formulations
ES13721874T Active ES2755081T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina
ES21203207T Active ES2972198T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina
ES19191600T Active ES2902573T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES13721874T Active ES2755081T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina
ES21203207T Active ES2972198T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina
ES19191600T Active ES2902573T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina

Country Status (12)

Country Link
US (10) US8431155B1 (https=)
EP (4) EP3620155B1 (https=)
JP (1) JP6180515B2 (https=)
KR (1) KR101593360B1 (https=)
AR (1) AR091351A1 (https=)
AU (3) AU2013256558B2 (https=)
BR (1) BR112014027087B1 (https=)
CA (1) CA2872300C (https=)
ES (4) ES3050125T3 (https=)
MX (2) MX363670B (https=)
UY (1) UY34776A (https=)
WO (1) WO2013165902A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP3524248A1 (en) 2007-06-21 2019-08-14 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
KR102240042B1 (ko) 2012-05-03 2021-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형
DK3445362T3 (da) 2016-04-20 2021-10-11 Veroscience Llc Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
US10426772B2 (en) 2016-05-16 2019-10-01 Regents Of The University Of Minnesota Use of ergot alkaloids as an anthelmintic agent
WO2019079623A1 (en) 2017-10-18 2019-04-25 Veroscience Llc ENHANCED BROMOCRIPTINE FORMULATIONS
US11607455B2 (en) 2019-09-23 2023-03-21 Veroscience Llc Method for inducing tumor regression

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659715A (en) 1986-03-07 1987-04-21 Louisiana State University And Agricultural And Mechanical College Method of inhibiting body fat stores
US4783469A (en) 1986-03-07 1988-11-08 Meier Albert H Method of inhibiting body fat stores
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5700800A (en) 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5744477A (en) 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US6004972A (en) 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5731287A (en) 1988-05-10 1998-03-24 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5344832A (en) 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5585347A (en) 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5668155A (en) 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5468755A (en) 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5830895A (en) 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5006526A (en) 1988-10-17 1991-04-09 Louisiana State University Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
IT1235053B (it) * 1989-04-07 1992-06-17 Poli Ind Chimica Spa Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti.
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5696128A (en) 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
GB9421836D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5565454A (en) 1995-05-31 1996-10-15 Ergo Science, Incorporated Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions
US5626860A (en) 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5792748A (en) 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
US5877183A (en) 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040077679A1 (en) 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20050054652A1 (en) 2002-07-29 2005-03-10 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
ES2625429T3 (es) 2003-01-23 2017-07-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050215558A1 (en) 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
DE602006006658D1 (de) 2005-03-04 2009-06-18 Nycomed Pharma As Verfahren zur herstellung von calciumzusammensetzungen im kontinuierlichen fliessbett
CN101868239B (zh) * 2006-01-05 2015-06-10 伊森舍丽斯有限公司 钾atp通道开放剂的盐及其用途
JP5215172B2 (ja) * 2006-04-13 2013-06-19 東亜薬品株式会社 乾式直打速崩壊性錠剤
CN101657186B (zh) * 2007-04-13 2012-07-18 陶氏环球技术公司 剂型用粒状材料
EP3524248A1 (en) 2007-06-21 2019-08-14 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US20210401824A1 (en) 2007-06-21 2021-12-30 Veroscience Llc Parenteral Formulations of Dopamine Agonists
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US7631155B1 (en) 2007-06-30 2009-12-08 Emc Corporation Thin provisioning of a file system and an iSCSI LUN through a common mechanism
CN101820873A (zh) * 2007-10-11 2010-09-01 麦仁斯有限公司 包含萘醌基化合物的微粉化粒子的药物组合物
JP5883382B2 (ja) 2009-06-05 2016-03-15 ヴェロサイエンス・エルエルシー 代謝障害の治療のためのドーパミン作動薬と第一相インスリン分泌促進薬の組合せ
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
WO2011156248A2 (en) 2010-06-08 2011-12-15 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
MX2013005705A (es) 2010-11-23 2013-09-16 Veroscience Llc Tratamiento terapeutico para sindrome metabolico, diabetes tipo 2, obesidad, o prediabetes.
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
US20150011554A1 (en) 2013-06-13 2015-01-08 Veroscience Llc Compositions and Methods for Treating Metabolic Disorders
DK3445362T3 (da) 2016-04-20 2021-10-11 Veroscience Llc Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
US20170340271A1 (en) 2016-05-26 2017-11-30 Veroscience Llc Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions
WO2019079623A1 (en) 2017-10-18 2019-04-25 Veroscience Llc ENHANCED BROMOCRIPTINE FORMULATIONS
US11607455B2 (en) 2019-09-23 2023-03-21 Veroscience Llc Method for inducing tumor regression

Also Published As

Publication number Publication date
US9522117B2 (en) 2016-12-20
US20200276193A1 (en) 2020-09-03
EP3620155B1 (en) 2021-10-20
AU2016202572A1 (en) 2016-05-19
JP6180515B2 (ja) 2017-08-16
US20160038424A1 (en) 2016-02-11
MX2014013158A (es) 2015-07-14
ES2902573T3 (es) 2022-03-29
UY34776A (es) 2013-11-29
AU2016202572B2 (en) 2018-02-01
US20210228576A1 (en) 2021-07-29
US8431155B1 (en) 2013-04-30
AU2013256558B2 (en) 2016-01-28
EP4342536A2 (en) 2024-03-27
US10307421B2 (en) 2019-06-04
EP3960160A1 (en) 2022-03-02
CA2872300A1 (en) 2013-11-07
EP3960160B1 (en) 2023-12-06
KR20150006461A (ko) 2015-01-16
EP3620155A1 (en) 2020-03-11
BR112014027087B1 (pt) 2021-03-02
EP4342536A3 (en) 2024-06-26
US11000522B2 (en) 2021-05-11
JP2015515984A (ja) 2015-06-04
EP4342536B1 (en) 2025-10-01
EP4342536C0 (en) 2025-10-01
EP2844229A1 (en) 2015-03-11
US8613947B2 (en) 2013-12-24
US20170340632A1 (en) 2017-11-30
US11666567B2 (en) 2023-06-06
US20180263978A1 (en) 2018-09-20
MX2019003619A (es) 2019-07-18
AU2018203021B2 (en) 2020-02-06
CA2872300C (en) 2016-08-16
US9700555B2 (en) 2017-07-11
AR091351A1 (es) 2015-01-28
US20190343833A1 (en) 2019-11-14
US9192576B2 (en) 2015-11-24
EP2844229B1 (en) 2019-09-11
AU2018203021A1 (en) 2018-05-24
ES2972198T3 (es) 2024-06-11
KR101593360B1 (ko) 2016-02-11
BR112014027087A2 (pt) 2017-06-27
WO2013165902A1 (en) 2013-11-07
US20130287848A1 (en) 2013-10-31
US9993474B2 (en) 2018-06-12
US20170020871A1 (en) 2017-01-26
MX363670B (es) 2019-03-29
US20240131026A1 (en) 2024-04-25
US10688094B2 (en) 2020-06-23
HK1208173A1 (en) 2016-02-26
US20140187560A1 (en) 2014-07-03
AU2013256558A1 (en) 2014-12-18
ES2755081T3 (es) 2020-04-21

Similar Documents

Publication Publication Date Title
ES3050125T3 (en) Bromocriptine formulations
US12616693B2 (en) Bromocriptine formulations
HK40026299B (en) Bromocriptine formulations
HK40026299A (en) Bromocriptine formulations
HK1208173B (en) Bromocriptine formulations